

STERLING BIOTECH LIMITED

Regd. Office: 43, Atlanta Building, Nariman Point, Mumbai - 400 021


CIN - L51900MH1985PLC035738

UNAUDITED FINANCIAL RESULTS FOR THE FOURTH QUARTER ENDED 31 DECEMBER 2015

(Rs. in Lacs)

Sr. No.	Particulars	Three Months ended			Twelve Months ended	
		31/12/2015	30/09/2015	31/12/2014	31/12/2015	31/12/2014
		Unaudited	Unaudited	(Refer Note No. 5)	Unaudited	Audited
1	Income from Operations					
	a) Net Sales/Income from Operations	8,630.94	10,703.44	12,162.82	41,086.94	66,695.07
	b) Other Operating Income	117.00	98.92	75.31	477.14	368.20
	c) Total Income from Operations	8,747.94	10,802.36	12,238.13	41,564.08	67,063.27
2	Expenses					
	a) Cost of materials consumed	6,578.84	6,358.94	8,796.93	38,239.05	61,783.87
	b) Purchase of stock-in-trade	0.00	0.00	0.00	0.00	0.00
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(572.71)	923.77	46.66	(10,545.05)	(15,232.62)
	d) Employee benefits expense	1,359.76	1,301.14	1,216.86	5,233.37	5,167.27
	e) Depreciation and amortization expense	7,021.73	7,020.70	8,480.34	28,109.00	27,657.43
	f) Other Expenses	807.91	731.75	932.21	3,124.16	3,852.80
	g) Total Expenses	15,195.53	16,336.30	19,473.00	64,160.53	83,228.75
3	Profit / (Loss) from Operations before Other Income and finance Costs (1-2)	(6,447.59)	(5,533.94)	(7,234.87)	(22,596.45)	(16,165.48)
4	Other Income	0.00	0.00	0.00	0.00	0.00
5	Profit / (Loss) from Ordinary activities before finance costs (3+4)	(6,447.59)	(5,533.94)	(7,234.87)	(22,596.45)	(16,165.48)
6	Finance Costs	8,920.00	8,411.97	8,759.83	33,188.37	46,950.57
7	Profit / (Loss) from Ordinary Activities after finance costs but before tax (5-6)	(15,367.59)	(13,945.91)	(15,994.70)	(55,784.82)	(63,116.05)
8	Tax expense					
	a) Current	0.00	0.00	0.00	0.00	0.00
	b) Deferred	(4,986.00)	(4,525.00)	(5,189.00)	(18,100.00)	(20,478.00)
	c) Total	(4,986.00)	(4,525.00)	(5,189.00)	(18,100.00)	(20,478.00)
9	Net Profit / (Loss) from Ordinary Activities after tax (7-8)	(10,381.59)	(9,420.91)	(10,805.70)	(37,684.82)	(42,638.05)
10	Extraordinary Items	0.00	0.00	0.00	0.00	0.00
11	Net Profit / (Loss) for the period (9+10)	(10,381.59)	(9,420.91)	(10,805.70)	(37,684.82)	(42,638.05)
12	Prior year adjustment	0.00	0.00	(1,932.47)	0.00	(3,132.47)
13	Profit available for appropriation	(10,381.59)	(9,420.91)	(12,738.17)	(37,684.82)	(45,770.52)
14	Paid-up equity share capital (Face Value of Re.1/- per share)	2,720.48	2,720.48	2,720.48	2,720.48	2,720.48
15	Paid-up Debt Capital #	N.A.	N.A.	N.A.	133,471.13	127,445.14
16	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year					101,026.03
17	Debenture Redemption Reserve	N.A.	N.A.	N.A.	4,982.14	4,982.14
18.i	Earnings Per Equity Share (EPS) (before extraordinary items) (F.V. of Re.1/- each) (not annualised)					
	a) Basic	(3.82)	(3.46)	(3.97)	(13.85)	(15.67)
	b) Diluted	(2.40)	(2.18)	(2.50)	(8.70)	(9.85)
18.ii	Earnings Per Equity Share (EPS) (after extraordinary items) (F.V. of Re.1/- each) (not annualised)					
	a) Basic	(3.82)	(3.46)	(4.68)	(13.85)	(16.82)
	b) Diluted	(2.40)	(2.18)	(2.94)	(8.70)	(10.57)
19	Debt Equity Ratio	N.A.	N.A.	N.A.	2.01	1.94
20	Debt Service Coverage Ratio (DSCR)	N.A.	N.A.	N.A.	0.04	0.07
21	Interest Service Coverage Ratio (ISCR)	N.A.	N.A.	N.A.	0.17	0.18

Paid-up Debt Capital represents Foreign Currency Convertible Bonds (FCCB)



STERLING BIOTECH LIMITED
 Regd. Office: 43, Atlanta Building, Nariman Point, Mumbai - 400 021
 CIN - L51900MH1985PLC035738

STANDALONE STATEMENT OF ASSETS AND LIABILITIES

(Rs. In Lacs)

Sr. No.	Particulars	STANDALONE	
		Twelve Months Ended	
		31/12/2015	31/12/2014
		Unaudited	Audited
A	EQUITY AND LIABILITIES		
1	SHAREHOLDERS' FUND		
a)	Share Capital	186,965.48	153,403.14
b)	Reserves and Surplus	63,341.22	101,026.03
c)	Money received against share warrants	0.00	0.00
	Sub - total Shareholders' Funds	250,306.70	254,429.17
2	Share Application money pending allotment	0.00	0.00
3	Non-current liabilities		
a)	Long-term borrowings	231,441.17	186,114.64
b)	Deferred tax liabilities (net)	0.00	0.00
c)	Other long-term liabilities	0.00	0.00
d)	Long-term provisions	0.00	0.00
	Sub-total - Non-current liabilities	231,441.17	186,114.64
4	Current liabilities		
a)	Short-term borrowings	98,309.45	118,171.45
b)	Trade payables	1,703.29	2,469.06
c)	Other current liabilities	147,835.33	160,069.08
d)	Short-term provisions	0.00	0.00
	Sub-total - Current liabilities	247,848.07	280,709.59
	TOTAL - EQUITY AND LIABILITIES	729,595.94	721,253.40
B	ASSETS		
1	Non-current assets		
a)	Fixed assets	545,779.39	554,396.88
b)	Goodwill on consolidation	0.00	0.00
c)	Non-current investments	16,897.72	16,890.75
d)	Deferred tax assets (net)	43,136.99	25,036.99
e)	Long-term loans and advances	0.00	0.00
f)	Other non-current assets	16,761.84	18,857.07
	Sub-total - Non-current assets	622,575.94	615,181.69
2	Current assets		
a)	Current investments	0.00	0.00
b)	Inventories	73,052.85	63,456.54
c)	Trade receivables	4,316.01	18,055.92
d)	Cash and cash equivalents	1,611.39	1,765.92
e)	Short-term loans and advances	28,039.75	22,793.33
f)	Other current assets	0.00	0.00
	Sub-total - Current assets	107,020.00	106,071.71
	TOTAL - ASSETS	729,595.94	721,253.40

Notes:

- The company's operations fall under single segment hence segment reporting as defined in Accounting Standard 17 is not applicable.
- The above Financial results have been reviewed by the Audit Committee and taken on record by the Board of Directors in its meeting held on 12 February 2016.
- The Statutory Auditors have carried out a limited review of the financial results for the quarter ended 31 December 2015.
- The Company has Overseas Subsidiary and there are no business operations in the subsidiary company.
- The Figures of the corresponding Quarter ended on 31 December 2014 are the Balancing figures between the audited figures in respect of the full financial year ended on 31 December 2014 and published year to date figures upto the third quarter ended on 30 September 2014.
- The Secured, Redeemable, Non Convertible Debentures (NCD) issued by the Company have fully matured in the year 2015 and the Company has not made the the repayment of the redemption amount and interest thereon.
- Previous period figures have been regrouped/reclassified, wherever necessary.

Place : Mumbai
 Date : 12 February 2016.

For and on Behalf of
 STERLING BIOTECH LIMITED

Chetan J. Sandesara
 Joint Managing Director
 (DIN:00255671)

